0925 ET - Restaurant executives say they haven't seen a big impact on their sales from GLP-1 weight-loss drugs, but they are prompting some concerns. Darden Restaurants says it's watching if the drugs curb sales at its fine-dining brands, which tend to attract higher-income consumers who could more readily afford the drugs. Fiscal 2Q same-store sales at Darden's fine-dining segment fell 5.8% as consumers who traded up to the brands last year are now more price conscious, shifting back to more affordable casual-dining, the company says. (heather.haddon@wsj.com; @heatherhaddon)
(END) Dow Jones Newswires
December 19, 2024 09:25 ET (14:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。